SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Carl Zeiss Meditec AG (CZMWF) trades at a trailing P/E of 19.8, forward P/E of 19.4. Trailing earnings yield is 5.06%, forward earnings yield 5.15%. PEG 10.79.
Criteria proven by this page:
- VALUE (75/100, Pass) — P/E is below market average (19.8); earnings yield beats bond yields (5.06%).
- Forward P/E 19.4 (down from trailing 19.8) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 10.79 — above 2.0 suggests expensive relative to earnings growth.
- Trailing Earnings Yield 5.06% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income. Forward yield improves to 5.15% as earnings recover.
Overall SharesGrow Score: 68/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
75/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — CZMWF
Valuation Multiples
P/E (TTM)19.8
Forward P/E19.4
PEG Ratio10.79
Forward PEG10.79
P/B Ratio0.00
P/S Ratio1.25
EV/EBITDA0.0
Per Share Data
EPS (TTM)$1.61
Forward EPS (Est.)$1.64
Book Value / Share$0.00
Revenue / Share$25.45
FCF / Share$0.00
Yields & Fair Value
Earnings Yield5.06%
Forward Earnings Yield5.15%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$1.21 |
$1.09B |
$98.33M |
9% |
| 2017 |
$1.57 |
$1.19B |
$134.45M |
11.3% |
| 2018 |
$1.41 |
$1.28B |
$126.46M |
9.9% |
| 2019 |
$1.79 |
$1.46B |
$159.76M |
10.9% |
| 2020 |
$1.37 |
$1.34B |
$122.39M |
9.2% |
| 2021 |
$2.64 |
$1.65B |
$236.28M |
14.3% |
| 2022 |
$3.29 |
$1.9B |
$293.91M |
15.4% |
| 2023 |
$3.25 |
$2.09B |
$290.4M |
13.9% |
| 2024 |
$2.01 |
$2.07B |
$178.73M |
8.7% |
| 2025 |
$1.61 |
$2.23B |
$141.21M |
6.3% |
